A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertesion

European Respiratory Journal

Volumn 27, Issue 3, 2006, Pages 578-584

  Robbins, I M ^a   Kawut, S M ^b,c   Yung, D ^b   Reilly, M P ^d   Lloyd, W ^a   Cunningham, G ^a   Loscalzo, J ^e   Kimmel, S E ^d   Christman, B W ^a   Barst, R J ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Columbia University ^*  (United States)

^c University of Pennsylvania School of Medicine ^*  (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aspirin; Clinical trial; Hypertension; Platelets; Pulmonary

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; BOSENTAN; CLOPIDOGREL; COLLAGEN; ICOSANOID; PADGEM PROTEIN; PLACEBO; PROSTACYCLIN; THROMBOXANE A2; THROMBOXANE B2;

ADULT; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG MECHANISM; FATTY ACID METABOLISM; FEMALE; HEMORRHOID HEMORRHAGE; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; MALE; NAUSEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SKIN BRUISING; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; ASPIRIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANE A2; TICLOPIDINE;

EID: 33644856615     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00095705     Document Type: Article

References (28)

1. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198-1206.
2. Nakonechnicov S, Gabbasov Z, Chazova I, Popov E, Belenkov Y. Platelet aggregation in patients with primary pulmonary hypertension. Blood Coagul Fibrinolysis 1996; 7: 225-227.
3. Lopes AA, Maeda NY, Almeida A, Jaeger R, Ebaid M, Chamone DF. Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension. Angiology 1993; 44: 701-706.
4. Sakamaki F, Kyotani S, Nagaya N, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000; 102: 2720-2725.
5. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
6. Dorn GW 2nd. Role of thromboxane A2 in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl 1997; 48: Suppl., 42-62.
7. Knapp HR, Healy C, Lawson J, FitzGerald GA. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. Thromb Res 1988; 50: 377-386.
8. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137-1141.
9. Langleben D, Christman BW, Barst RJ, el al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002; 143: E4.
10. Rich S, Hart K, Kieras K, Brundage BH. Thromboxane synthetase inhibition in primary pulmonary hypertension. Chest 1987; 91: 356-360.
11. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-302.
12. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.
13. Olschewski H, Simonneau. G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
14. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
15. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischernic Events (CURE) Trial. Circulation 2004; 110: 1202-1208.
16. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 2004; 15: 117-125.
17. Robbins IM, Barst RJ, Rubin LJ, et al. Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertension. Chest 2001; 120: 1639-1644.
18. Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001; 37: 2036-2041.
19. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-688.
20. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186.
21. Hauth J, Sibai B, Caritis S, et al. Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medical Units. Am J Obstet Gynecol 1998; 179: 1193-1199.
22. Cipollone F, Ciabattoni G, Patrignani P, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102: 1007-1013.
23. Hurlen M, Seljeflot I, Arnesen H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res 2000; 99: 487-494.
24. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 1994; 89: 1951-1957.
25. Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995; 26: 1581-1585.
26. Robbins IM, Morrow JD, Christman BW. Oxidant stress but not thromboxane decreases with epoprostenol therapy. Free Radic Biol Med 2005; 38: 568-574.
27. Arrebola MM, De la Cruz JP, Villalobos MA, Pinacho A, Guerrero A, Sanchez de la Cuesta F. In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J Cardiovasc Pharmacol 2004; 43: 74-82.
28. Cella G, Bellotto F, Tona F, et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001; 120: 1226-1230.